News and Announcements
OncoSil strengthens management team
- Published October 08, 2015 11:14AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th October 2015, ASX Announcement
OncoSil Medical Limited (ASX:OSL) (OncoSil Medical, the Company) is pleased to announces details of two new key appointments to its senior management team in preparation for the commercialisation of the Company’s OncoSilTM localised radiation treatment for cancer.
Mr David James appointed Global Head of Manufacturing Operations
Mr David James has been appointed the Company’s Global Head of Manufacturing Operations on a full-time basis effective from 5 October 2015, after initially working in the role in a part-time consultancy capacity since February.
Mr James is a highly experienced pharmaceutical manufacturing operations executive with more that 20 years’ experience in this field, including six years with leading cancer treatment company Sirtex Medical (ASX:SRX) as Global Operations Manager.
Dr Greg Rogers appointed Manufacturing Engineering Manager
The Company is also pleased to advise the appointment of Dr Greg Rogers as Manufacturing Engineering Manager, effective from 2 Novemebr 2015.
To read the full announcement please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
